Skip to content
HCC Buddy home

C92.62 ICD-10-CM Code: Acute myeloid leukemia with 11q23-abnormality in relapse

C92.62 maps to CMS-HCC V28 17. A source-labeled RAF reference is available. Confirm the documented diagnosis and applicable coding requirements. MEAT criteria · RAF Calculator · HCC Buddy coding tools

ICD-10-CM Code View

HCC Buddy Code Card

Digital ICD-10 code-book layout with official code detail, always-visible risk models, Code Trumping, and Buddy coding guidance.

Code lookupC92.62

FY 2026 Apr update / Neoplasms (C00-D49) / Malignant neoplasms of lymphoid, hematopoietic and related tissue (C81-C96)

C92.62

Billable / SpecificICD-10-CMOfficial ICD-10-CMCodebook guidance

Acute myeloid leukemia with 11q23-abnormality in relapse

A specific type of acute myeloid leukemia with a chromosomal abnormality (11q23) where the cancer has returned after a period of remission.

Buddy the Bee presenting code insight

Buddy Insight

Acute myeloid leukemia with 11q23-abnormality in relapse indicates recurrence of this cytogenetically defined AML subtype after prior remission.

OverviewRisk ModelsCode BookDocumentationAuditNotesEdition comparison

CMS-HCC V28

HCC 17

Coefficient HCC 17: 4.209 (Community Non-Dual Aged (CNA))

CMS-HCC V24

Historical

Historical

Not used for CY2026 payment

ACA/HHS

HCC 008

Code-level coefficient reference

ESRD/PACE

HCC 8

Code-level coefficient reference

RXHCC

HCC 19

Code-level coefficient reference

Code Book Path

Official
C92Myeloid leukemiaC92.6Acute myeloid leukemia with 11q23-abnormalityC92.62Acute myeloid leukemia with 11q23-abnormality in relapse

Inclusion Terms

Official
  • Acute myeloid leukemia with variation of MLL-geneInherited from C92.6

Excludes 2

Official
  • Kaposi's sarcoma of lymph nodes (C46.3)Inherited from C81-C96
  • secondary and unspecified neoplasm of lymph nodes (C77.-)Inherited from C81-C96
  • secondary neoplasm of bone marrow (C79.52)Inherited from C81-C96
  • secondary neoplasm of spleen (C78.89)Inherited from C81-C96

Related Codes

Official
C92.60Acute myeloid leukemia with 11q23-abnormality not having achieved remissionC92.61Acute myeloid leukemia with 11q23-abnormality in remission

Includes

Official
  • granulocytic leukemiaInherited from C92
  • myelogenous leukemiaInherited from C92

Excludes 1

Official
  • personal history of leukemia (Z85.6)Inherited from C92

Code First

Official

No Code First sequencing instructions are included in this display for C92.62. Check the code and parent instructions in the Code Book.

Use Additional

Official

No Use Additional Code instructions are included in this display for C92.62. Check the code and parent instructions in the Code Book.

Code Also

Official
  • , if applicable, pancytopenia (acquired) (D61.818)Inherited from C92

Buddy Documentation Tip

HCC Buddy guidance
Documentation must confirm prior remission and relapse with the 11q23/KMT2A rearrangement, ideally confirmed at relapse as clonal evolution may occur.
Duration of first remission, prior treatment regimens, and updated molecular/cytogenetic testing at relapse must be recorded.
Transplant candidacy assessment, donor search status, and salvage treatment plan should be documented.

MEAT Support

HCC Buddy guidance
Documentation must confirm prior remission and relapse with the 11q23/KMT2A rearrangement, ideally confirmed at relapse as clonal evolution may occur.
Duration of first remission, prior treatment regimens, and updated molecular/cytogenetic testing at relapse must be recorded.
Transplant candidacy assessment, donor search status, and salvage treatment plan should be documented.

Audit Caution

HCC Buddy guidance
Confirm the 11q23 rearrangement persists at relapse, as some relapses may show clonal evolution with loss of the original abnormality or acquisition of new changes.
Therapy-related AML at relapse may have different biology than de novo disease.
Duration of first remission (less than vs.
greater than 12 months) is a key prognostic factor that should be documented.

Common Mistakes

HCC Buddy guidance
C92.60 (AML with 11q23 not in remission) is for primary refractory disease.
C92.61 (AML with 11q23 in remission) is for controlled disease.
C92.02 (AML in relapse) is less specific and does not capture the cytogenetic abnormality.
C92.52 (AMML in relapse) may overlap clinically but does not specify the 11q23 abnormality.

Current with CMS: FY2026 ICD-10-CM Apr 1 update (effective Apr 1 – Sep 30, 2026) · CMS-HCC V28, 100% phased in for payment year 2026. FY2027 code set already staged for October 1, 2026. How HCC Buddy stays current →

Is C92.62 an HCC code?

Yes. C92.62 (Acute myeloid leukemia with 11q23-abnormality in relapse) maps to HCC 17, Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic under the CMS-HCC V28 risk adjustment model, with a source-labeled community non-dual aged reference coefficient of 4.209. Source-labeled code-level coefficients are references, not member totals. Actual contribution depends on complete member context, hierarchy and cleanup rules, interactions, and model year. HCC Buddy's RAF Calculator supports CMS-HCC V28 PY2026 and shows no score unless every required source and calculation check passes. It is billable for payment year 2026.

Coder answer: C92.62 is billable and maps to V28 HCC 17, Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic. Open it in the Code Book for the tabular path, RAF, and MEAT checklist.

Code
C92.62
Description
Acute myeloid leukemia with 11q23-abnormality in relapse
HCC (V28)
HCC 17 — Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic
RAF reference coefficient
4.209
Billable
Yes
Payment year
2026

HCC Category Mapping

V28HCC 17, Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic
4.209
ESRDHCC 8, Metastatic Cancer and Acute Leukemia
Not separately weighted
RxHCCHCC 19, Leukemias and Other Hematologic Cancers
Not separately weighted

These are source-labeled model coefficients, not member totals. A category may still be removed by hierarchy or model cleanup rules. Weights are not directly comparable across models: CMS-HCC V28 and V24 use Community, Non-Dual, Aged; ESRD uses the dialysis continuing-enrollee model; RxHCC is the Part D continuing-enrollee, non-low-income, aged weight (a larger scale than CMS-HCC). ACA/HHS has no single weight — it varies by metal level. Actual per-patient RAF contribution depends on member context, hierarchy and cleanup rules, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains available for historical review.

Work C92.62 in the Code Book — tabular path, V28 RAF reference, and MEAT checklist →

MEAT review for C92.62

For C92.62, confirm that the documentation supports the diagnosis and meets the applicable coding, encounter, program and payer requirements. MEAT (Monitor, Evaluate, Assess, or Treat) is a review mnemonic, not a universal CMS coding rule.

  • MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
  • EEvaluate: test results, medication response, or physical findings reviewed by the provider
  • AAssess: explicit mention in the assessment or plan with acknowledgment of status
  • TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis

Coder workflow notes

Get the V28 mapping + MEAT cheat sheet

One printable reference: check representative V28 mappings and the documentation reminders your note needs. Free, no card.

Free PDF. No card. Unsubscribe anytime.

What This Code Means

C92.62 is the ICD-10-CM diagnosis code for acute myeloid leukemia with 11q23-abnormality in relapse. A specific type of acute myeloid leukemia with a chromosomal abnormality (11q23) where the cancer has returned after a period of remission. C92.62 sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neoplasms of lymphoid, hematopoietic and related tissue (c81-c96).

Under the CMS-HCC V28 risk adjustment model, C92.62 maps to Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic (HCC 17) with a source-labeled community, non-dual, aged reference coefficient of 4.209. No V24 mapping is shown for C92.62; use the applicable model and payment year when reviewing the V28 mapping. For CY2026 non-PACE Medicare Advantage, CMS uses 100% of the 2024 CMS-HCC model (V28). PACE uses a separate model blend. Source-labeled code-level coefficients are references, not member totals. Actual contribution depends on complete member context, hierarchy and cleanup rules, interactions, and model year. HCC Buddy's RAF Calculator supports CMS-HCC V28 PY2026 and shows no score unless every required source and calculation check passes.

Document both the cytogenetic abnormality and the relapse status in the medical record. For C92.62, confirm that the documentation supports the diagnosis and meets the applicable coding, encounter, program and payer requirements. MEAT (Monitor, Evaluate, Assess, or Treat) is a review mnemonic, not a universal CMS coding rule. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.

HCC Buddy maintains structured V28 and V24 mapping, source-labeled coefficient references, and MEAT documentation criteria for C92.62 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.

Coding Tips

  • •Document both the cytogenetic abnormality and the relapse status in the medical record
  • •Distinguish between initial presentation and relapse based on treatment history

Clinical Significance

Acute myeloid leukemia with 11q23-abnormality in relapse indicates recurrence of this cytogenetically defined AML subtype after prior remission. Relapsed AML with 11q23 rearrangements carries a poor prognosis, though outcomes vary by the specific fusion partner. Salvage therapy followed by allogeneic stem cell transplantation offers the best chance for long-term survival in eligible patients.

Documentation Requirements

  • ✓Documentation must confirm prior remission and relapse with the 11q23/KMT2A rearrangement, ideally confirmed at relapse as clonal evolution may occur.
  • ✓Duration of first remission, prior treatment regimens, and updated molecular/cytogenetic testing at relapse must be recorded.
  • ✓Transplant candidacy assessment, donor search status, and salvage treatment plan should be documented.

Commonly Confused Codes

  • •C92.60 (AML with 11q23 not in remission) is for primary refractory disease.
  • •C92.61 (AML with 11q23 in remission) is for controlled disease.
  • •C92.02 (AML in relapse) is less specific and does not capture the cytogenetic abnormality.
  • •C92.52 (AMML in relapse) may overlap clinically but does not specify the 11q23 abnormality.

Child Codes

C92.60Acute myeloid leukemia with 11q23-abnormality not having achieved remission
HCC 17
C92.61Acute myeloid leukemia with 11q23-abnormality in remission
HCC 17
C92.62Acute myeloid leukemia with 11q23-abnormality in relapse
HCC 17

Code Hierarchy

└C92Myeloid leukemia└C92.6Acute myeloid leukemia with 11q23-abnormality└C92.62Acute myeloid leukemia with 11q23-abnormality in relapse
└C92.62Acute myeloid leukemia with 11q23-abnormality in relapse

Also searched as

  • C92 62
  • C9262

For C92.62, confirm that the documentation supports the diagnosis and meets the applicable coding, encounter, program and payer requirements. MEAT (Monitor, Evaluate, Assess, or Treat) is a review mnemonic, not a universal CMS coding rule.

C92.62 maps to CMS-HCC V28 category 17, Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic. See the ICD-10 to HCC mapping hub for how the V28 crosswalk works. The mapping identifies a payment HCC category for C92.62. Review its source-labeled HCC coefficient above, check the RAF Calculator with complete member context for CMS-HCC V28 PY2026, and confirm the documentation the chart needs before the code is submitted. HCC Buddy shows no RAF score unless every required source and calculation check passes.

More on C92.62

Code family

Every C92 code with its CMS-HCC V28 statusMyeloid leukemia, 30 billable codes

Work C92.62 in HCC Buddy

Open C92.62 in the Code Book for the full Index-to-Tabular path, MEAT checklist, and V28 HCC mapping, or in the Encoder to code from a keyword search. Pro includes 7 days to try everything, no card required.

Open in Code BookOpen in EncoderStart Pro